Evidence map›Paper›PMID 41410715›Full record

ArticleFamilial cancer2025

Functional characterization of splice variants in hereditary breast and ovarian cancer susceptibility genes.

Laura Rosado-Jiménez, Younes Mestre-Terkemani, Ángeles García-Aliaga, María D Sarabia-Meseguer, Miguel Marín-Vera, José A Macías-Cerrolaza, Pilar Sánchez-Henarejos, María R García-Hernández, Marta Zafra-Poves, Beatriz C Álvarez-Abril and 10 more

Abstract read
PubMed Publisher
In one paragraph

Article in Familial cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Laura Rosado-JiménezDepartment of Clinical Analysis, Genomics Laboratory, Clinical University Hospital Virgen de la Arrixaca, Murcia, Spain. laurarosadojimenez@gmail.com.
Younes Mestre-TerkemaniDepartment of Clinical Analysis, Genomics Laboratory, Clinical University Hospital Virgen de la Arrixaca, Murcia, Spain.
Ángeles García-AliagaDepartment of Clinical Analysis, Genomics Laboratory, Clinical University Hospital Virgen de la Arrixaca, Murcia, Spain.
María D Sarabia-MeseguerDepartment of Clinical Analysis, Genomics Laboratory, Clinical University Hospital Virgen de la Arrixaca, Murcia, Spain.
Miguel Marín-VeraDepartment of Medical Oncology, Clinical University Hospital Virgen de la Arrixaca, Murcia, Spain.
José A Macías-CerrolazaDepartment of Medical Oncology, Clinical University Hospital Morales Meseguer, Murcia, Spain.
Pilar Sánchez-HenarejosDepartment of Medical Oncology, Clinical University Hospital Virgen de la Arrixaca, Murcia, Spain.
María R García-HernándezDepartment of Medical Oncology, Clinical University Hospital Virgen de la Arrixaca, Murcia, Spain.
Marta Zafra-PovesDepartment of Medical Oncology, Clinical University Hospital Morales Meseguer, Murcia, Spain.
Beatriz C Álvarez-AbrilDepartment of Medical Oncology, Clinical University Hospital Morales Meseguer, Murcia, Spain.
Carmen B López-SánchezDepartment of Medical Oncology, Clinical University Hospital Virgen de la Arrixaca, Murcia, Spain.
María P Moya-MartínezDepartment of Medical Oncology, Clinical University Hospital Morales Meseguer, Murcia, Spain.
Patricia Pascual-GilabertDepartment of Clinical Analysis, Genomics Laboratory, Clinical University Hospital Virgen de la Arrixaca, Murcia, Spain.
Ana M Cerón-MorenoDepartment of Clinical Analysis, Genomics Laboratory, Clinical University Hospital Virgen de la Arrixaca, Murcia, Spain.
Verónica Castillo-GuardiolaDepartment of Clinical Analysis, Genomics Laboratory, Clinical University Hospital Virgen de la Arrixaca, Murcia, Spain.
David Antón-MartínezDepartment of Clinical Analysis, Genomics Laboratory, Clinical University Hospital Virgen de la Arrixaca, Murcia, Spain.
Francisco Ayala-de la PeñaDepartment of Medical Oncology, Clinical University Hospital Morales Meseguer, Murcia, Spain.
José L Alonso-RomeroBiomedical Research Institute of Murcia (IMIB), Murcia, Spain.
José A Noguera-VelascoDepartment of Clinical Analysis, Genomics Laboratory, Clinical University Hospital Virgen de la Arrixaca, Murcia, Spain.
Francisco Ruiz-EspejoDepartment of Clinical Analysis, Genomics Laboratory, Clinical University Hospital Virgen de la Arrixaca, Murcia, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hereditary breast and ovarian cancer (HBOC) is an autosomal dominant cancer predisposition syndrome primarily associated with germline mutations in BRCA1 and BRCA2. Nevertheless, the implementation of multigene panels using Next Generation Sequencing (NGS) has expanded the mutational spectrum for this hereditary syndrome. As a result, the number of variants of uncertain clinical significance (VUS) has increased, and their functional and clinical interpretations remains a challenge for genetic counseling. This article reports three splice variants in susceptibility genes detected in women diagnosed with invasive ductal breast cancer. According to in silico predictions, these splicing-disrupting mutations in cancer susceptibility genes are likely to be pathogenic. Splicing functional assays were performed by reverse transcription polymerase chain reaction (RT-PCR) followed by capillary electrophoresis and Sanger sequencing. The characterization of these splicing events has enabled the identification of variants susceptible to alternative or abnormal splicing and their clinical classification according to the consensus criteria of the American College of Medical Genetics and Genomics-Association for Molecular Pathology (ACMG-AMP). This research increases our current knowledge about splice variants, thereby improving diagnostic performance and their clinical classification to support appropriate genetic counseling.

Indexed as

Breast NeoplasmsCarcinoma, Ductal, BreastGenetic Predisposition to DiseaseHereditary Breast and Ovarian Cancer SyndromeAdultAlternative SplicingBRCA1 ProteinBRCA2 ProteinCheckpoint Kinase 2FemaleGerm-Line MutationHumansMiddle AgedOvarian NeoplasmsRNA SplicingBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanCheckpoint Kinase 2CHEK2 protein, humanBRCABreast/ovarian cancer susceptibility genesCHEK2SplicingTP53Variant classification

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.